114 related articles for article (PubMed ID: 15001974)
1. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity.
Duguay Y; Báár C; Skorpen F; Guillemette C
Clin Pharmacol Ther; 2004 Mar; 75(3):223-33. PubMed ID: 15001974
[TBL] [Abstract][Full Text] [Related]
2. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients.
Holthe M; Rakvåg TN; Klepstad P; Idle JR; Kaasa S; Krokan HE; Skorpen F
Pharmacogenomics J; 2003; 3(1):17-26. PubMed ID: 12629580
[TBL] [Abstract][Full Text] [Related]
3. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy.
Holthe M; Klepstad P; Zahlsen K; Borchgrevink PC; Hagen L; Dale O; Kaasa S; Krokan HE; Skorpen F
Eur J Clin Pharmacol; 2002 Aug; 58(5):353-6. PubMed ID: 12185559
[TBL] [Abstract][Full Text] [Related]
4. Variability in UDP-glucuronosyltransferase genes and morphine metabolism: observations from a cross-sectional multicenter study in advanced cancer patients with pain.
Fladvad T; Klepstad P; Langaas M; Dale O; Kaasa S; Caraceni A; Skorpen F
Pharmacogenet Genomics; 2013 Mar; 23(3):117-26. PubMed ID: 23277092
[TBL] [Abstract][Full Text] [Related]
5. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease.
Darbari DS; van Schaik RH; Capparelli EV; Rana S; McCarter R; van den Anker J
Am J Hematol; 2008 Mar; 83(3):200-2. PubMed ID: 17724700
[TBL] [Abstract][Full Text] [Related]
6. The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants.
Yang ZZ; Li L; Wang L; Yuan LM; Xu MC; Gu JK; Jiang HD; Yu LS; Zeng S
Acta Pharmacol Sin; 2017 Aug; 38(8):1184-1194. PubMed ID: 28552915
[TBL] [Abstract][Full Text] [Related]
7. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.
Innocenti F; Liu W; Fackenthal D; Ramírez J; Chen P; Ye X; Wu X; Zhang W; Mirkov S; Das S; Cook E; Ratain MJ
Pharmacogenet Genomics; 2008 Aug; 18(8):683-97. PubMed ID: 18622261
[TBL] [Abstract][Full Text] [Related]
8. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
Kuypers DR; Naesens M; Vermeire S; Vanrenterghem Y
Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms and haplotypes of the UDP-glucuronosyltransferase 2B7 gene promoter.
Hu DG; Meech R; Lu L; McKinnon RA; Mackenzie PI
Drug Metab Dispos; 2014 May; 42(5):854-62. PubMed ID: 24561451
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms in the 5'-flanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation.
Nakamura A; Nakajima M; Higashi E; Yamanaka H; Yokoi T
Pharmacogenet Genomics; 2008 Aug; 18(8):709-20. PubMed ID: 18622263
[TBL] [Abstract][Full Text] [Related]
11. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1.
Aklillu E; Carrillo JA; Makonnen E; Hellman K; Pitarque M; Bertilsson L; Ingelman-Sundberg M
Mol Pharmacol; 2003 Sep; 64(3):659-69. PubMed ID: 12920202
[TBL] [Abstract][Full Text] [Related]
13. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
Lévesque E; Delage R; Benoit-Biancamano MO; Caron P; Bernard O; Couture F; Guillemette C
Clin Pharmacol Ther; 2007 Mar; 81(3):392-400. PubMed ID: 17339869
[TBL] [Abstract][Full Text] [Related]
14. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.
Innocenti F; Iyer L; Ramírez J; Green MD; Ratain MJ
Drug Metab Dispos; 2001 May; 29(5):686-92. PubMed ID: 11302935
[TBL] [Abstract][Full Text] [Related]
15. Environmental and genetic factors associated with morphine response in the postoperative period.
Coulbault L; Beaussier M; Verstuyft C; Weickmans H; Dubert L; Trégouet D; Descot C; Parc Y; Lienhart A; Jaillon P; Becquemont L
Clin Pharmacol Ther; 2006 Apr; 79(4):316-24. PubMed ID: 16580900
[TBL] [Abstract][Full Text] [Related]
16. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine.
Sawyer MB; Innocenti F; Das S; Cheng C; Ramírez J; Pantle-Fisher FH; Wright C; Badner J; Pei D; Boyett JM; Cook E; Ratain MJ
Clin Pharmacol Ther; 2003 Jun; 73(6):566-74. PubMed ID: 12811366
[TBL] [Abstract][Full Text] [Related]
17. Brain-derived neurotrophic factor involved epigenetic repression of UGT2B7 in colorectal carcinoma: A mechanism to alter morphine glucuronidation in tumor.
Yang ZZ; Li L; Xu MC; Ju HX; Hao M; Gu JK; Jim Wang ZJ; Jiang HD; Yu LS; Zeng S
Oncotarget; 2017 Apr; 8(17):29138-29150. PubMed ID: 28418861
[TBL] [Abstract][Full Text] [Related]
18. Promoter activity of human tissue inhibitor of metalloproteinase 2 gene with novel single nucleotide polymorphisms.
Hegab AE; Sakamoto T; Uchida Y; Nomura A; Ishii Y; Morishima Y; Mochizuki M; Kimura T; Saitoh W; Iizuka T; Kiwamoto T; Sekizawa K
Respirology; 2005 Jan; 10(1):27-30. PubMed ID: 15691234
[TBL] [Abstract][Full Text] [Related]
19. Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter.
Ishii Y; Hansen AJ; Mackenzie PI
Mol Pharmacol; 2000 May; 57(5):940-7. PubMed ID: 10779377
[TBL] [Abstract][Full Text] [Related]
20. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy.
Hirota T; Ieiri I; Takane H; Sano H; Kawamoto K; Aono H; Yamasaki A; Takeuchi H; Masada M; Shimizu E; Higuchi S; Otsubo K
Drug Metab Dispos; 2003 May; 31(5):677-80. PubMed ID: 12695358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
